| Company Name: |
ShangHai Caerulum Pharma Discovery Co., Ltd.
|
| Tel: |
18149758185 18149758185 |
| Email: |
sales-cpd@caerulumpharma.com |
| Products Intro: |
Product Name:Tarloxotinib bromide，PR-610
CAS:1636180-98-7
Purity:98% Package:1g;10g;100g
|
Tarloxotinib bromide manufacturers
- Tarloxotinib bromide
-
- $143.00 / 1mg
-
2026-05-11
- CAS:1636180-98-7
- Min. Order:
- Purity: 99.52%
- Supply Ability: 10g
- Tarloxotinib bromide
-
- $143.00 / 1mg
-
2026-04-21
- CAS:1636180-98-7
- Min. Order:
- Purity: 99.52%
- Supply Ability: 10g
|
| | Tarloxotinib bromide Basic information |
| | Tarloxotinib bromide Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO:30.0(Max Conc. mg/mL);44.0(Max Conc. mM) | | form | Solid | | color | Light yellow to yellow |
| | Tarloxotinib bromide Usage And Synthesis |
| Uses | Tarloxotinib Bromide is a kinase inhibitor prodrug useful in the treatment of cancer. | | in vivo | A prototypic WT EGFR driven xenograft model (A431) is used to benchmark Tarloxotinib bromide activity against each EGFR-TKI by “retrotranslation” of reported plasma exposure for each agent in human subjects back to the xenograft model. Only treatment with clinically relevant doses and schedules of Tarloxotinib bromide is associated with tumor regression and durable inhibition of WT EGFR tumor phosphorylation. Consistent with these findings, Tarloxotinib bromide treatment can also regress the WT EGFR NSCLC tumor models H125 and H1648, demonstrating Tarloxotinib bromide provides the necessary therapeutic index to inhibit WT EGFR in vivo[1]. | | IC 50 | EGFR/HER2 |
| | Tarloxotinib bromide Preparation Products And Raw materials |
|